Published on 6 Aug 2023 on Simply Wall St. via Yahoo Finance
Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL)
Celebrations may be in order for Precision BioSciences, Inc. (NASDAQ:DTIL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects.
After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of performance. The loss per share is expected to ameliorate slightly, reducing to US$0.72. However, before this estimates update, the consensus had been expecting revenues of US$30m and US$0.93 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
See our latest analysis for Precision BioSciences